All In Biotech

Investigational drug · Phase 2

OCU400

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Retinitis Pigmentosa, Leber Congenital Amaurosis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "OCU400"

First trial start

2022

Jan 24, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "OCU400", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Retinitis Pigmentosa
  • Leber Congenital Amaurosis

Approved drugs for the same conditions: Rare and genetic disease · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "OCU400" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Retinitis Pigmentosa

  • BS01Phase 22 trials

    Bionic Sight LLC · Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

  • CPK850Phase 21 trial

    Novartis · Retinitis Pigmentosa

  • famzeretcelhuman retinal progenitor cells, jCellPhase 21 trial

    jCyte, Inc · Retinitis Pigmentosa

  • KIO-301Phase 21 trial

    Kiora Pharmaceuticals, Inc. · Retinitis Pigmentosa

  • SPVN06Phase 21 trial

    SparingVision · Retinitis Pigmentosa

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.